Tyra Biosciences, Inc.
Tyra Biosciences, Inc.
Your view on TYRA
Overview
What the company does, where it operates, and who runs it.
About Tyra Biosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Todd Harris
- Headquarters
- 2656 State Street, Carlsbad, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Todd Harris
- Headquarters
- 2656 State Street, Carlsbad, CA, US
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.
The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers.
In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Tyra Biosciences, Inc., and the rating behind it. TYRA last traded at $22.03; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Tyra Biosciences, Inc.. Starting points for Tyra Biosciences, Inc.: EPS -$2.25, beta 0.73 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Tyra Biosciences, Inc.. Tyra Biosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Tyra Biosciences, Inc.. Trailing twelve-month EPS for Tyra Biosciences, Inc. stands at -$2.25. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Tyra Biosciences, Inc.. Tyra Biosciences, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Tyra Biosciences, Inc. valued side by side against its closest peers. Tyra Biosciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Tyra Biosciences, Inc., and how their positions are changing. At a $1.31B market value, institutional positions materially move Tyra Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Tyra Biosciences, Inc. executives and directors. Shares of Tyra Biosciences, Inc. have traded between $6.42 and $17.27 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Tyra Biosciences, Inc.. Tyra Biosciences, Inc. is a $1.31B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Tyra Biosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Tyra Biosciences, Inc.. Coverage tracks Tyra Biosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.